Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114.
Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115.
Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25236-25242. doi: 10.1073/pnas.1914056116. Epub 2019 Nov 25.
Sickle cell disease (SCD) is caused by a variant hemoglobin molecule that polymerizes inside red blood cells (RBCs) in reduced oxygen tension. Treatment development has been slow for this typically severe disease, but there is current optimism for curative gene transfer strategies to induce expression of fetal hemoglobin or other nonsickling hemoglobin isoforms. All SCD morbidity and mortality arise directly or indirectly from polymer formation in individual RBCs. Identifying patients at highest risk of complications and treatment candidates with the greatest curative potential therefore requires determining the amount of polymer in individual RBCs under controlled oxygen. Here, we report a semiquantitative measurement of hemoglobin polymer in single RBCs as a function of oxygen. The method takes advantage of the reduced oxygen affinity of hemoglobin polymer to infer polymer content for thousands of RBCs from their overall oxygen saturation. The method enables approaches for SCD treatment development and precision medicine.
镰状细胞病 (SCD) 是由一种变异的血红蛋白分子引起的,该分子在低氧张力下在红细胞 (RBC) 内聚合。对于这种通常严重的疾病,治疗方法的发展一直很缓慢,但目前对诱导胎儿血红蛋白或其他非镰状血红蛋白同工型表达的治愈性基因转移策略持乐观态度。所有 SCD 的发病率和死亡率都直接或间接地源于个体 RBC 中的聚合物形成。因此,确定并发症风险最高的患者和具有最大治愈潜力的治疗候选者,需要在受控氧的情况下确定个体 RBC 中的聚合物数量。在这里,我们报告了一种半定量测量单个 RBC 中血红蛋白聚合物随氧变化的方法。该方法利用血红蛋白聚合物对氧的亲和力降低的特性,从整体氧饱和度推断出数千个 RBC 的聚合物含量。该方法为 SCD 治疗开发和精准医学提供了途径。